Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - crizotinib - capsules - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive. xalkori is indicated for the treatment of patients with metastatic nsclc whose tumors are ros1-positive.

European Union - English - myHealthbox

pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

European Union - English - myHealthbox

pfizer limited - crizotinib - hard capsules - 250 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - crizotinib (unii: 53ah36668s) (crizotinib - unii:53ah36668s) - crizotinib 250 mg - xalkori is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk) or ros1-positive as detected by an fda-approved test [see dosage and administration (2.1)] . xalkori is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is alk-positive. limitations of use : the safety and efficacy of xalkori have not been established in older adults with relapsed or refractory, systemic alk-positive alcl. xalkori is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (imt) that is alk-positive. none. risk summary based on findings from animal studies and its mechanism of action, xalkori can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available dat

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; calcium hydrogen phosphate; iron oxide red; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - crizotinib, quantity: 200 mg - capsule, hard - excipient ingredients: titanium dioxide; gelatin; calcium hydrogen phosphate; colloidal anhydrous silica; microcrystalline cellulose; iron oxide red; magnesium stearate; sodium starch glycollate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - xalkori is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc). xalkori is indicated for the treatment of patients with ros1-positive advanced non-small cell lung cancer (nsclc).

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - crizotinib -